Insights from CTTACC: immune system reset by cellular therapies for chronic illness after trauma, infection, and burn
Cytotherapy: the official journal of the International Society for Cell & Gene Therapy(ISCT)
Kenneth Bertram, Charles Cox, Hasan Alam, Clifford Lowell, Joseph Cuschieri, Biju Parekkadan, Shibani Pati
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells
bioRxiv : the preprint server for biology
Cytotherapy: the official journal of the International Society for Cell & Gene Therapy(ISCT)
Kasap C, Adila Izgutdina, Bonell PatiñoEscobar, Amrik Kang, Nikhil Chilakapati, Naomi Akagi, Haley Johnson, Tasfia Rashid, Juwita Werner, Abhilash Barpanda, Huimin Geng, Yu-Hsiu T. Lin, Sham Rampersaud, Daniel Gil-Alós, Amin Sobh, Daphné Dupéré-Richer, Gianina Wicaksono, K.M. Kawehi Kelii, Radhika Dalal, Emilio Ramos, Anjanaa Vijayanarayanan, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Ons Zakraoui, Isa Tariq, Veronica Steri, Mala Shanmugam, Lawrence H. Boise, Tanja Kortemme, Elliot Stieglitz, Jonathan D. Licht, William J. Karlon, Benjamin G. Barwick, Arun P. Wiita
Dr. Arun Wiita's group releases a new preprint to BioRxiv, describing the discovery of CD70 as a novel CAR T cell target enriched in high-risk multiple myeloma. While BCMA-directed CAR Ts are highly effective in this disease, patients with high-risk genotypes relapse most quickly after this therapy. Dr. Wiita's group further used structure-guided design to develop an anti-CD70 CAR with much greater in vivo expansion than standard antibody fragment-based CARs. This design describes a promising strategy for clinical translation in this unmet medical need.